146445-04-7

Upstream product

• 76-83-5 trityl chloride 
• 50894-62-7 (R)-prolinamide hydrochloride 
• 596-43-0 bromo-triphenyl-methane 
• 62937-45-5 (R)-prolinamide 

Downstream Products

• 1204651-52-4 C₃₂H₃₁IN₂O 
• 1204651-53-5 N-{[(2R)-1-(2-Fluoroethyl)pyrrolidin-2-yl]methyl}-2-(4-iodophenyl)-acetamide 
• 1204651-51-3 2-(4-Iodophenyl)-N-[(2R)-pyrrolidin-2-ylmethyl]acetamide 
• 146445-07-0 (R)-(-)-2,3-dimethoxy-5-iodo-N-(2-pyrrolidinylmethyl)benzamide 
• 146445-06-9 5-Iodo-2,3-dimethoxy-N-((R)-1-trityl-pyrrolidin-2-ylmethyl)-benzamide 
• 660851-66-1 ethyl N,N-diisopropyl-N'-(N-trityl-D-prolyl)phosphorodiamidite 
• 660851-67-2 N⁷-tert-butoxycarbonyl-2',3'-O-isopropylidene-8-oxoadenosine 5'-[ethyl N-(N-trityl-D-prolyl)phosphoramidate] 

Relevant academic research and scientific papers

Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT

A novel series of dual-labeling D2 dopamine agents (labeled with either 18F or 123I for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2- fluoroethoxy)-5

PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The present invention relates to pyridopyridone derivatives of formula (I): in which the variables are as defined herein, to their preparation and to their therapeutic use as inhibitors of the kinase activity of PDGF (platelet-derived growth factor) ligand receptors and possibly of FLT3 (fms-like tyrosine kinase receptor) ligand receptors.